Biologic persistance rates consistently lower in women vs men with PsA. 52% vs 62% @ 1 year. Some statistically significant, but really it is a consistent message across drugs. We urgently need research on the reasons. Abstr#0779 #ACR23 @RheumNow https://t.co/Kfk3k3LJ44 https://t.co/SmiOnt7D4d

🆕 Imaging modality: MSOT multispectral optoacoustic tomography Findings PsA enthesis -Hyperemia ↗️ oxygenation So2 and Hboxy -Reduction Collagen concentration -Lipids substitution But surprise PSO pts display similar signs despite abs of symptoms! @RheumNow ABST0750 #ACR23 https://t.co/qWMvmIRd7j

2 yrs extension of DRESS-PS study 100+ pts w/ PsA and AxSPA -70% LDA state in both Ctrl & Intervention gps -strong recovery after relapse No difference efficacy protocolized & routine care tapering but inferior TNFi use (52 vs. 77%) in Intervention gp @RheumNow #ACR23 ABST0775 https://t.co/V2DqCjT0w3

#ACR23 IV secukinumab vs placebo at 52 Weeks @RheumNow https://t.co/4zQa37tN4l

Phase 3 Study of IV Secukinumab for treatment of PsA - efficacious and safety profile similar to Subq version ~60% ACR 50 response maintained at week 52 2nd responses of MDA, PASI90, enthesitis, dactylitis resolution met @RheumNow #ACR23 Abs#0776 https://t.co/jikWd4fnGm

Is exercise safe in PsO/PsA? Ab0497 #ACR23 US of entheses before & after 60 min of badminton 🏸 7 PsA pts, 9 PsO pts, 196 US scans acquired. No signif change in VAS pain/tender entheses 4 pts w grade 1 doppler at 6 entheses, butnon-tender 1 pt w active PsA had worsening @RheumNow https://t.co/nsi9b6px0X

Ab#498 Does DMARD for PsO and PsA decrease MACE? #ACR23 @RheumNow Retrospective database Israeli study. PsO, PsA on MTX or bDMARD: lower MACE compared to health matched controled (HR 0.45-0.68, p<0.001) Pts on topical Rx had marginally Increased MACE (HR 1.14, p <0.001) https://t.co/0uRgjzYbFp

BKZ tx resulted in sustained improvements in pt‑reported pain and fatigue from Wk 16 - 52 in bDMARD-naïve and TNFi-IR pts w/ active PsA, w/ clinically meaningful improvements observed in >50% of pts in BE-OPTIMAL & BE-COMPLETE #ACR23 Abs 0527 https://t.co/AQKYUubKLl @rheumnow https://t.co/WsXlhENzL1

EISER study: Undiagnosed IBD in SpA Abs#0495 #ACR23 @RheumNow 559 pts, 47% PsA/53% SpA (80% r-AxSpA) Higher mean fecal calprotectin in r-AxSpA (395 vs 305 nrAxSpA/PsA) 14.6% IBD symptoms, 23 patients (4.4% were dx w IBD) Fecal calprotectin & history can uncover IBD #ACRBest

High hs-CRP predicts PsO -> PsA? Abs#0484 #ACR23 @RheumNow 589 PsO pts wo PsA, followed mean 7.5 years 57 pts developed PsA (1.2 events/yr) Higher levels of b/l hs-CRP seen w: arthrlalgia, obesity, females Higher hs-CRP ass. w/ PsA - p=0.002, but HR only 1.03 (CI 1.01-1.05)

Systemic anti-inflammatory treatments for PsO and PsA including methotrexate and biologics provided cardioprotective effects Potential cardiovascular benefits of IL-17i and IL-12/23i compared to TNFi @RheumNow #ACR23 Abs#0498 https://t.co/Np7PSNvFd6

Long term safety data for bimekizumab (IL17i) in Psa & axSpA Overall as expected; increased infections (esp fungal/candida) & hepatic events No new signals... uveitis flares is interesting Need H2H of IL17's! IXE vs SEC vs BIM @RheumNow #ACR23 Abstr 0511 https://t.co/pBqly2JylA

Deucravacitinib (TYK2) data has been surprisngly good in SLE Strong rationale in PsA as well; I liked this poster & the focus on pain scores / patient QOL Probably my #1 draft pick for "drugs I'm buying right now" @RheumNow #ACR23 Abstr0508 https://t.co/FHNvgUrYxp

There is a high concordance (84.4%) of physician and patient global assessment of psoriatic arthritis disease activity from 538 paired assessments in the ARLAR multinational study, Maroof A et al, Abst #0506 #ACR23 @RheumNow https://t.co/NsT4MNWPVX https://t.co/TfuMj8qMXz